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Introduction: The contribution of Th17 cytokines to autoimmune thyroid
disease (AITD) is generally accepted. However, the roles of Th17 cells in the
initiation and progression of Hashimoto's thyroiditis (HT) and Graves' disease
(GD) remain unclear. Selenium deficiency, along with genetic predisposition
and environmental factors, may have a role in thyroid autoimmunity.
Aim: We aimed to assess (1) the Th17 immune response by measuring plasma
levels of Th17‐ and Treg‐associated cytokines and (2) the selenium status in
treatment‐naïve Latvian patients with newly diagnosed GD or HT.
Methods: Eleven GD patients, 41 HT patients, and 26 healthy subjects were
recruited for this study. Plasma levels of IL‐17a, IL‐22, IL‐23, IL‐6, and IL‐10 were
detected by xMAP technology, while selenium was detected fluorometrically.
Results and Conclusions: No significant differences in IL‐17a, IL‐22, IL‐23,
IL‐6, or IL‐10 levels were found among the HT patients, GD patients, and
controls. In the HT patients, IL‐17a levels were positively correlated with
IL‐22, IL‐23, IL‐6, and IL‐10, while IL‐22 was correlated with IL‐6, IL‐23,
and IL‐10. In the GD patients, IL‐17a levels were positively correlated with
IL‐22, IL‐23, and IL‐10; IL‐22 was positively correlated with IL‐23, IL‐6, and
IL‐10; FT3 was positively correlated with IL‐17a, IL‐23, and IL‐10; and FT4
was positively correlated with IL‐17a and IL‐10 levels. Plasma selenium levels
were negatively correlated with antithyroid peroxidase antibody titers in the
HT patients. Although no difference in selenium levels was observed between
the AITD patients and controls, the selenium status of the Latvian patients
with GD or HT was at a suboptimal level.
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1 | INTRODUCTION
Autoimmune thyroid disease (AITD), predominantly
presenting as Graves' disease (GD) or Hashimoto's thyr-
oiditis (HT), is the most frequent autoimmune disease
with increasing prevalence and incidence in recent dec-
ades. In both autoimmune disorders, the complex inter-
actions among various environmental and endogenous
factors trigger thyroid autoimmunity in predisposed in-
dividuals, leading to enhanced thyroid autoantigen pre-
sentation and impairment of immune tolerance.1 In HT
development, enhanced secretion of interferon (IFN)‐γ,
interleukin (IL)‐1β, IL‐2, and tumor necrosis factor
(TNF)‐α paralleled by thyroid cell apoptosis occurs due to
the impaired T helper (Th)‐1‐based immune response,
whereas in GD, upregulated production of IL‐4, IL‐5,
IL‐6, and IL‐13, resulting from the Th2‐driven humoural
response, causes the secretion of autoantibodies re-
cognizing thyroid‐stimulating hormone receptor (anti‐
TSHR) and hypertrophic changes.2
The understanding of the Th1 and Th2 cell dichot-
omy, which is essential for autoimmune disorders, shif-
ted with the discovery of Th17 lymphocytes. Supporting
evidence suggesting the contribution of Th17 cells and
pro‐inflammatory IL‐17 to AITD, particularly HT, has
been produced in the last decade.3–6 It has been proposed
that AITD results from Th1/Th2 dichotomy and Th17/T
regulatory (Treg) cell imbalances.7 Th17 lymphocytes
mainly secrete IL‐17 and IL‐22. IL‐17 is a critical pro‐
inflammatory cytokine mediating chronic and auto-
immune inflammation and neutrophil recruitment. Act-
ing on immune and nonimmune cells such as epithelial
cells, endothelial cells, fibroblasts, and osteoclasts, IL‐17
promotes the expression of various cytokines (IL‐1β,
TNF‐α, IL‐6, IL‐8, granulocyte macrophage colony‐
stimulating factor [GM‐CSF], and granulocyte colony‐
stimulating factor), chemokines (CXCL1, CXCL5, and
CCL2), and metalloproteinases by cells.8 The initial de-
velopment of Th17 cells from naïve Th cells is induced by
transforming growth factor (TGF)‐β in the presence of
IL‐6 and IL‐21, while IL‐23 and IL‐1β are vital for both
the complete maturation and stabilization of the Th17
phenotype.9,10 To date, the association between selenium
and Th17‐related cytokines has been insufficiently ex-
plored, mostly in experimental models.
Currently, a role for selenium deficiency in the de-
velopment of AITD is suggested along with genetic pre-
disposition and environmental triggers. Selenium
deficiency can impair the differentiation of CD4+ T cells,
leading to cellular and humoural response dysfunction.
Selenium leads to changes in the levels of IL‐6, TGF‐β,
and IL‐23 and may further contribute to impaired dif-
ferentiation of Th17 cells.11 Very little information is
currently available on the selenium content in soils in
Latvia or the selenium status in AITD.
In this study, we aimed to assess (1) the Th17 im-
mune response in AITD by measuring the plasma con-
centrations of Th17‐ and Treg‐associated cytokines and
(2) the selenium status in Latvian patients with newly
diagnosed, treatment‐naïve GD or HT to determine
whether the selenium level is reduced in AITD patients
compared to healthy subjects without autoimmune
disorders.
2 | MATERIALS AND METHODS
2.1 | Patients
Eleven adult patients with untreated newly diagnosed
hyperthyroid GD and 41 patients with untreated new‐
onset HT were recruited into this prospective study
between January and November 2020 at the Depart-
ment of Endocrinology, Riga East University Hospital,
Latvia. Thirty‐three out of 41 HT patients were eu-
thyroid (median TSH, 1.90 [1.00–2.62] μIU/ml), and 8
out of the 41 patients had mild subclinical hypothyr-
oidism (median TSH, 5.90 [5.41–7.35] μIU/ml). The
median age was 36 (27–50.5) years for the HT pa-
tients, 41 (29–62) years for the GD patients, and 30
(27–42.25) years for the control group (p = .139). The
diagnosis of AITD was confirmed by evaluating the
clinical manifestations of GD and HT, complemented
by biochemical thyroid tests and ultrasound imaging.
The control group consisted of 26 age‐ and sex‐
matched healthy subjects without any autoimmune
disease and with normal thyroid function, who were
negative for anti‐thyroid peroxidase autoantibodies
(anti‐TPO), anti‐thyroglobulin autoantibodies (anti‐
Tg), antinuclear antibodies (ANAs), and anti‐tissue‐
transglutaminase IgA (tTG‐IgA) autoantibodies.
The exclusion criteria for the study included
(1) pregnancy; (2) presence of malignancy, active infection,
chronic inflammatory, or other autoimmune disease; (3) use
of selenium‐containing commercial supplements; (4) vege-
tarian or vegan diet; (5) use of medications affecting thyroid
and immune function (amiodarone, corticosteroids, non-
steroidal anti‐inflammatory drugs, antidepressants, or antic-
onvulsants); and (6) significant renal or hepatic impairment.
The study protocol was conducted according to the
Declaration of Helsinki and approved by the Riga East
Hospital Research Committee and the Central Medi-
cal Ethics Committee, Latvia (Decision No. 01‐29.1/
5033). All patients and volunteers provided written
informed consent before enrollment and blood sample
collection.
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2.2 | Blood collection
Peripheral blood samples were collected from all 86 pa-
tients and volunteers after overnight fasting early in the
morning. Thereafter, the samples were centrifuged at
1500 rpm for 10 min and stored at −80°C until analysis.
Venous blood samples were collected from hyperthyroid
and hypothyroid patients before therapy with methima-
zole or levothyroxine, respectively.
2.3 | Thyroid function and antibody
tests
The levels of serum‐free thyroxine (FT4), free triio-
dothyronine (FT3), and thyroid‐stimulating hormone
(TSH), as well as anti‐TPO and anti‐Tg were measured by
chemiluminescence immunoassay (Siemens) performed
on an Advia Centaur XP (Siemens) analyzer. The normal
values were as follows: FT4, 0.7–1.48 ng/dl; FT3,
0.2–0.44 ng/dl; and TSH, 0.35–4.94 μIU/ml; anti‐TPO,
0‐5.61 IU/ml; anti‐Tg, 0‐40 U/ml. The levels of anti‐TSHR,
ANAs, and tTG‐IgA autoantibodies were measured by
ELISA (Pharmacia Diagnostics Freiburg) according to the
manufacturer's instructions (reference range: anti‐TSHR,
0–1.58 IU/L; ANA, reference range would be “negative”;
tTG‐IgA, 0–10.0 U/ml).
2.4 | Cytokines detection
Cytokine patterns analyzed in the current study included
the following groups: Th17‐related cytokines (IL‐17a and
IL‐22), Th17‐promoting cytokines (IL‐23 and IL‐6), and a
Treg‐associated cytokine (IL‐10). EDTA plasma im-
munological markers were detected by xMAP technology
(Magpix system; Luminex Corporation). All tests were
performed in accordance with the manufacturer's in-
structions (Cat#: HTH17MAG‐14K; Kit Lot#: 3323752;
Milliplex). The limit of detection for each cytokine was as
follows: IL‐17a, 0.009 pg/ml; IL‐22, 0.021 ng/ml; IL‐23,
0.098 ng/ml; IL‐6, 1.7 pg/ml; and IL‐10, 0.3 pg/ml.
2.5 | Selenium assay
The plasma selenium concentration was determined
fluorometrically by using the fluorescence spectro-
photometer “Cary Eclipse” (Varian, Inc.).12 Inter‐
laboratory quality control was conducted by employing
two standards—a selenium AAS solution (Cat# 24, 792‐8;
Sigma‐Aldrich) and Seronorm TE Serum Level I (Cat#
201 405; Sero AS)—for the Seronorm™ Trace Elements‐
Controls Programme. External quality assessment ser-
vices were provided by Labquality Oy (Finland). The
lower detection limit for selenium was 4 µg/L.
2.6 | Statistical analysis
The normal distribution of data was confirmed by
D'Agostino and Pearson, Anderson–Darling, and
Shapiro–Wilk normality tests. Homogeneity of variances
was tested using Brown–Forsythe and Bartlett's tests. As
dispersion did not correspond to a normal distribution in
most cases, data were analyzed by the nonparametric
Kruska–Wallis H test followed by the two‐stage step‐up
method of Benjamini, Krieger, and Yekutieli as a post
hoc procedure, and the results are displayed as the
median and interquartile range. Depending on the data
distribution, both parametric Pearson's analysis and
nonparametric Spearman's correlation analysis were
performed to determine the relationships of studied
parameters. p< .05 was considered statistically sig-
nificant for all statistical tests. All graphical images and
statistical analyses were performed using GraphPad
Prism 9.0 for MacOS software (GraphPad Software).
3 | RESULTS
The demographic and biochemical characteristics of the
participants are presented in Table 1. HT patients were
stratified into two groups according to their serum TSH
level: euthyroid (0.354≤ TSH≤ 4.94 μIU/ml; n= 33) and
hypothyroid (4.94 < TSH< 10 μIU/ml; n= 8) patients.
No significant differences in IL‐17a, IL‐22, IL‐23, IL‐6, or
IL‐10 levels were found among the patients with HT,
patients with GD and controls (all p> .05) (Figure 1).
Interleukin levels also did not differ between the eu-
thyroid and hypothyroid HT patients (all p> .05). The
plasma levels of cytokines are summarized in Table 2.
When the relationships among Th17‐related cyto-
kines were investigated, we found that in HT patients,
the plasma levels of IL‐17a were positively correlated
with the levels of IL‐22, IL‐23, IL‐6, and IL‐10
(Figure 2A); additionally, IL‐22 was correlated with
IL‐6, IL‐23, and IL‐10 (Figure 2B). Similarly, in GD pa-
tients, positive associations between IL‐17a and the levels
of IL‐22, IL‐23, and IL‐10 were found; however, IL‐17a
was not correlated with IL‐6 (Figure 3A). There were
positive correlations between the levels of IL‐22 and
those of IL‐23, IL‐6, and IL‐10 in patients with GD as well
(Figure 3B). Positive relationships between different in-
terleukins were revealed in the control group and both
euthyroid HT patients and hypothyroid HT patients.
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TABLE 1 Demographic and biochemical characteristics of the participants
HT patients (n= 41) GD patients (n= 11) Controls (n= 26) p
Sex (female/male) 39/2 9/2 21/5 .152
Age (years) 36 (27–50.5) 41 (29–62) 30 (27–42.25) .139
TSH (μIU/ml) 2.16 (1.42–3.77) 0.0003 (0.0000–0.0004) 1.11 (0.96–1.67) <.001
FT4 (ng/dl) 0.91 (0.85–0.98) 1.97 (1.76–2.55) 0.94 (0.91–1.07) <.001
FT3 (ng/dl) 0.32 (0.29–0.35) 1.21 (1.04–2.47) 0.32 (0.30–0.35) <.001
Anti‐TPO (IU/ml) 202.99 (75.80–421.40) 121.04 (3.74–929.28) 0.46 (0.25–0.78) <.001
Anti‐Tg (U/ml) 0.00 (0.00–51.02) 5.96 (0.00–43.46) <20
Anti‐TSHR (IU/L) <1.58 9.18 (4.05–19.68) <1.58
Note: Data are presented as the median (interquartile range). The Kruskal–Wallis test was used to calculate the p value for comparisons among three groups for
non‐normally distributed data.
Abbreviations: FT3, triiodothyronine; FT4, thyroxine; GD, Graves' disease; HT, Hashimoto's thyroiditis; Tg, thyroglobulin; TPO, thyroid peroxidase;
TSH, thyroid‐stimulating hormone; TSHR, thyroid‐stimulating hormone receptor.
p< .05: statistically significant.
FIGURE 1 Comparisons of plasma IL‐17a, IL‐22, IL‐23, IL‐6, and IL‐10 levels among patients with HET (n= 33), HHT (n= 8), or GD
(n= 11) and healthy subjects (n= 26). The dot plots represent the quantified data for (A) IL‐17a, (B) IL‐22, (C) IL‐23, (D) IL‐6, and (E) IL‐10
plasma levels. (A–E) Each dot represents a single data point. ns, not significant; GD, Graves' disease; HET, Hashimoto's thyroiditis,
euthyroidism; HHT, Hashimoto's thyroiditis, hypothyroidism
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TABLE 2 Plasma levels of interleukins in the study groups
HT patients (n= 41)
GD





IL‐17a (pg/ml) 14.83 (10.37–19.75) 13.53 (10.33–16.72) 16.43 (9.14–19.75) .906
12.95 (10.18–19.18) 15.99 (12.38–39.37) .606
IL‐22 (ng/ml) 0.08 (0.00–0.47) 0.13 (0.00–0.25) 0.25 (0.00–0.54) .393
0.026 (0.000–0.351) 0.421 (0.054–1.138) .180
IL‐23 (ng/ml) 2.45 (1.35–4.49) 2.31 (1.70–3.36) 3.23 (1.86–4.64) .653
2.37 (1.30–3.76) 3.42 (2.06–8.18) .408
IL‐6 (pg/ml) 5.88 (0.00–36.24) 6.92 (0.00–24.90) 11.61 (0.00–59.50) .682
1.90 (0.00–14.93) 68.62 (8.67–148.25) .059
IL‐10 (pg/ml) 9.70 (6.35–15.21) 9.50 (6.54–11.11) 11.62 (6.70–17.04) .658
9.70 (5.96–13.47) 9.83 (7.03–26.90) .585
Note: Data are presented as the median (interquartile range). The Kruskal–Wallis test was used to calculate the p value for comparisons among three groups for
non‐normally distributed data.
Abbreviations: GD, Graves' disease; HT, Hashimoto's thyroiditis.
p< .05: statistically significant.
FIGURE 2 Relationships between (A) IL‐17a or (B) IL‐22 and the studied biomarkers in the Hashimoto's thyroiditis patient group
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Variance–covariance matrices with Spearman's rank
correlation coefficients and p values representing the
association level between studied cytokines in the patient
groups are given in Figure 4.
Moreover, no significant correlations were found be-
tween the levels of interleukins and thyroid auto-
antibodies, TSH, FT3 or FT4 in HT patients (all p> .05).
However, in newly diagnosed GD patients, the levels of
FT3 were positively correlated with IL‐17, IL‐23, and
IL‐10 (Figure 5A), while FT4 was positively correlated
with IL‐17 and IL‐10 levels (Figure 5B). In addition, anti‐
TSHR autoantibody titers were not correlated with the
levels of interleukins in the GD group (all p> .05).
The median plasma selenium levels were 85.03
(60.09–116.60) µg/L for HT patients, 71.33 (59.05–
104.42) µg/L for GD patients, and 80.35 (67.15–113.67) µg/L
for control participants (Table 3). The plasma selenium
distribution in the patient groups is presented in Figure 6A.
The levels of selenium did not differ significantly among the
studied groups (Figure 6B). Similarly, no differences in se-
lenium levels were observed between euthyroid HT patients
and HT patients with subclinical hypothyroidism (Table 3).
Interestingly, we found that plasma selenium levels showed
a negative correlation with anti‐TPO autoantibody titers in
patients with HT (r=−.376; p= .02) (Figure 7). In addition,
significantly lower selenium levels were observed in HT
patients with higher anti‐TPO levels (≥400 IU/ml) than in
those with lower autoantibody titers (<400 IU/ml) (72.75
[52.10–88.43] vs. 89.04 [65.53–117.51] µg/L, respec-
tively; p= .05).
When the associations between plasma selenium and
cytokines were analyzed, no significant correlations were
found between selenium levels and the plasma levels of
IL‐17a, IL‐22, IL‐23, IL‐6, and IL‐10 for all groups (all
p> .05). The levels of selenium failed to correlate with
other characteristics, such as age, titers of anti‐Tg and
anti‐TSHR, TSH, FT3, and FT4 (all p> .05).
4 | DISCUSSION
Cytokines, along with T cell receptors, transcription
factors, and the intestinal microbiota, are important
factors regulating the Th17/Treg cell balance. Th17 cells
have been implicated in the development of auto-
immunity, whereas Treg cells producing IL‐10, IL‐35,
and TGF‐β maintain self‐tolerance and protect against
thyroid autoimmunity. Moreover, IL‐10 is a principal
FIGURE 3 Relationships between (A) IL‐17a or (B) IL‐22 and the studied biomarkers in the Graves' disease patient group
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anti‐inflammatory cytokine that has been shown to in-
hibit Th17 cell‐mediated inflammation.13 Furthermore,
current evidence suggests the Th17 lineage is plastic and
heterogeneous.7 Another pro‐inflammatory cytokine
contributing to thyroid autoimmunity is IL‐23. Produced
by antigen‐presenting cells such as macrophages and
dendritic cells, IL‐23 is crucial for the differentiation of
pathogenic Th17 lymphocytes.14 Furthermore, it has
been found to stimulate the survival of highly pathogenic
Th17 cells.
Only limited data are available for serum IL‐23 and
IL‐22 levels in AITD patients. Shi et al.15 demonstrated
upregulated messenger RNA (mRNA) expression of IL‐
17 and the Th17‐related transcription factor RORγt in
peripheral blood mononuclear cells along with elevated
plasma levels of IL‐17 and IL‐23 in newly diagnosed HT
patients. More recently, Konca Degertekin et al.3 de-
monstrated lower serum levels of IL‐17 and IL‐23 in
hypothyroid HT patients than in euthyroid patients, thus
suggesting that hypothyroidism has an inhibitory impact
on Th17 cytokine responses. However, no differences in
IL‐17 or IL‐23 levels were found between hypothyroid
HT patients and healthy subjects. Elevated levels of
serum IL‐23 were found in untreated euthyroid HT pa-
tients compared with controls, reflecting the early course
of thyroiditis, in a study conducted by Ruggeri et al.16 Jia
et al.17 observed increased serum levels of IL‐23 in GD
patients. In contrast, Figueroa‐Vega et al.4 did not find
any significant differences in IL‐23 levels between GD
patients and healthy subjects. Previously, we demon-
strated thyrocyte‐related IL‐23 overexpression in HT pa-
tients, while no difference was found between GD and
colloid goiter patients, suggesting that IL‐23 may be less
implicated in GD pathogenesis than in HT
pathogenesis.18
IL‐22 produced by Th17 cells can also be secreted by
another novel subset of Th cells—CCR+IL‐17−IL‐22+
(Th22) cells. We failed to demonstrate any differences in
IL‐22 levels among the three groups of subjects enrolled
in this study. However, Ruggeri et al.19 found sig-
nificantly increased serum levels of IL‐22 in untreated
euthyroid HT patients compared with patients with
nodular goiter or healthy subjects. In another study,
drug‐naïve HT patients suffering from overt or sub-
clinical hypothyroidism exhibited elevated serum levels
of IL‐17, while no differences were found in IL‐22 or
FIGURE 4 Variance–covariance matrices with Spearman's rank correlation coefficients (values in small squares) representing the
association level between studied cytokines in patient groups. GD, Graves' disease; HET, Hashimoto's thyroiditis, euthyroidism;
HHT, Hashimoto's thyroiditis, hypothyroidism. *p< .05; **p< .01; ***p< .001; ****p< .0001
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FIGURE 5 Associations of (A) fT3 or (B) fT4 with the studied biomarkers in the GD patient group. ns, not significant; *p< .05;
**p< .01. fT3, triiodothyronine; fT4, thyroxine; GD, Graves' disease; TSHR, thyroid‐stimulating hormone receptor
TABLE 3 Plasma levels of selenium in the study groups
HT patients (n= 40)
Euthyroid HT (n= 32) Hypothyroid HT (n= 8) GD patients (n= 11) Controls (n= 21) p
Se (µg/L) 85.03 (60.09–116.60) 71.33 (59.05–104.42) 80.35 (67.15–113.67) .763
85.03 (60.09–116.56) 94.78 (47.46–117.02) .886
Note: Data are presented as the median (interquartile range).
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IL‐23 levels between the HT patients and healthy in-
dividuals. Song et al.20 reported that peripheral blood
Th22 cell levels, serum IL‐22 levels, and IL‐22 mRNA
expression were elevated in GD patients compared with
controls, suggesting that IL‐22 may participate in the
initiation of GD. Similar to the results confirmed in the
present study, significant differences in the Th22 profile
were not found in HT patients.
In this study, positive correlations between the
levels of IL‐22, IL‐17a, IL‐23, and thyroid hormones
were found in newly diagnosed GD patients. How-
ever, no correlations between the levels of inter-
leukins and thyroid‐specific autoantibodies were
found. These results suggest that Th17 cytokines may
have a stimulatory effect on the severity of hy-
perthyroidism independent of autoantibody levels. No
such correlation was found in the HT group as a vast
majority of the recruited HT patients presented as
euthyroid. Due to the limited availability of
treatment‐naïve patients, only a small number of GD
patients was recruited. Therefore, the results of GD
group analyses must be concluded and interpreted
with caution because of the small sample size in this
group.
Among the nongenetic factors involved in the pa-
thogenesis of thyroid autoimmunity, high iodine intake,
and a low selenium status appear to be the most im-
portant. Previous studies have suggested the im-
munomodulatory and protective role of selenium and
selenoproteins. It has been suggested that selenium de-
ficiency presents with inhibition of selenoproteins and
altered secretion of IL‐10, IL‐12p40, and IFN‐γ, leading to
Th1/Th2 imbalance by shifting the balance toward Th1
responses.21 Additionally, glutathione peroxidase (GPx)1‐
deficient Th lymphocytes demonstrate a shift toward Th1
cells and attenuate the differentiation of Th cells into the
Th17 lineage.22 In another study, selenium supple-
mentation exerted protective effects against oxidative
stress and peroxide‐induced cell damage in human
thyrocytes and fibroblasts.23 However, more data from
clinical studies are needed for understanding the re-
lationship between selenium supplementation, immune
FIGURE 6 Histograms showing the frequency distribution of plasma selenium (A) and comparison of selenium levels (B) in patient
groups. (B) Each dot represents a single data point. GD, Graves' disease; HET, Hashimoto's thyroiditis, euthyroidism; HHT, Hashimoto's
thyroiditis, hypothyroidism; ns, not significant
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response, and antioxidant effects. In the current study,
we did not find any correlations between the plasma le-
vels of selenium and interleukins within the patient
groups, indicating that adequate selenium intake does
not skew the differentiation of CD4+ T cells toward the
Th1 or Th2 lineage and that Th1/Th2 differentiation is
largely determined by the pattern of secreted cytokines,
transcription factors, and other environmental signals.
In a population‐based Danish study, Pedersen et al.24
explored serum selenium levels in patients with newly di-
agnosed AITD. The authors found significantly lower sele-
nium levels in patients with GD than in controls; however,
no difference in serum selenium levels between HT patients
and healthy subjects was observed. In 2014, a multicentre,
cross‐sectional study was conducted in Austria, Greece, Ro-
mania, and Italy to assess the selenium status of euthyroid
patients with thyroid autoimmunity and those with non‐
autoimmune thyroid diseases.25 The study confirmed the
presence of a strong positive correlation between the plasma
levels of selenium and selenoprotein P (SePP), indicating a
less‐than‐optimal selenium status in these European coun-
tries. Additionally, significantly lower plasma selenium levels
were found in patients with GD or HT than in those with
non‐autoimmune thyroid disease, suggesting that selenium
supplementation might be beneficial in the case of thyroid
autoimmunity. Federige et al.26 also explored serum sele-
nium and SePP levels in AITD patients. Similar to the cur-
rent study, no difference in serum selenium levels was found
among HT patients, HT+LT4 patients, GD patients with or
without GO, and healthy individuals, although SePP levels
were lower in the GO and HT patients than in the control
subjects.
Various plasma or whole‐blood selenium cut‐offs have
been proposed by different authors to reflect selenium suf-
ficiency. The activity of GPx3 in human serum is used as a
marker of selenium sufficiency. It has been shown that the
plasma selenium level needed to optimize platelet GPx ac-
tivity is 100–115 μg/L, as proposed by Alfthan et al.,27 or
95μg/L according to Thomson et al.,28 whereas a plasma
selenium range of 88–142 µg/L is associated with the max-
imal SePP1 concentration.29 A selenium level below 80 μg/L
is considered to indicate an inadequate selenium status.30,31
The aforementioned cut‐offs suggest that 35% of the HT
patients and 36.4% of the GD patients enrolled in the study
had plasma selenium levels necessary for saturation of GPx,
while 47.5% of the HT patients and 63.3% of the GD patients
had a poor selenium status. The frequency of selenium de-
ficiency in the control group was 47.6%.
5 | CONCLUSIONS
Despite the recent data on the involvement of the IL‐17/IL‐
23 axis in the development of thyroid autoimmunity avail-
able in the literature, we did not find any significant differ-
ences in the plasma levels of Th17‐associated cytokines
between patients with AITD and control subjects. However,
a positive correlation between Th17 ILs was detected in both
HT patients and GD patients. Furthermore, Th17 cytokines
were positively correlated with the severity of hyperthyr-
oidism, suggesting their possible role in GD pathogenesis. A
few limitations should be considered when interpreting our
data. Although simultaneous assessment of various cyto-
kines provided more information on the complex cytokine
pattern that characterizes AITD, a small number of AITD
patients may lead to a possible loss of statistical significance.
Due to the lack of data regarding the levels of other Treg
cytokines, it will be of interest to further pursue studies of
Th17 and Treg cells as important players in AITD patho-
genesis. Although no difference in selenium levels was ob-
served between AITD patients and controls, the selenium
status of Latvian patients with newly diagnosed GD or HT
was at a suboptimal level. Interestingly, plasma selenium
levels were negatively correlated with anti‐TPO autoantibody
titers in HT patients. Moreover, HT patients with higher
anti‐TPO levels had lower levels of selenium, suggesting that
these patients might benefit from selenium supplementation.
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